NEW YORK — Applied DNA Sciences said on Tuesday that it has signed a one-year agreement to provide its Linea COVID-19 RT-PCR test to Stony Brook University Hospital (SBUH).
The PCR-based test, which received Emergency Use Authorization from the US Food and Drug Administration in May, is designed to detect target sequences of the SARS-CoV-2 spike gene. In April, Applied DNA partnered with SBUH to validate the test.
Under the terms of their agreement, Applied DNA will supply the test to Stony Brook, New York-based SBUH on an as-needed basis. The company said that it has already received an initial purchase order under the agreement but did not disclosed the terms.
Applied DNA said that it has designed and implemented an automated, high-throughput SARS-CoV-2 testing workflow in the SBUH clinical lab. This workflow includes equipment, software, and leased services including robotic RNA extraction, robotic sample preparation, and RT-PCR custom software.
"Our assay kit used in conjunction with the high-throughput workflows implemented by the company at SBUH's clinical lab gives SBUH a strong testing infrastructure to enable the testing of multiple affiliated populations, including patients, staff, and our surrounding community," Applied DNA President and CEO James Hayward said in a statement.
Stony Brook, New York-based Applied DNA said it would offer similar equipment arrangements to other diagnostics labs.